Peptides DB
Research-centric peptide and protocol reference hub
Study 32 of 33Survodutide (BI 456906) literatureDigestive diseases (Basel, Switzerland) · Meta-analysis · Phase 22023

GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.

GLP-1/glucagon dual receptor agonists may enhance MASH resolution and reduce liver fat, but further research is needed to confirm these findings and assess long-term effects.

Read at Digestive diseases (Basel, Switzerland)Add to compare

Where it sits

this study against the rest of the survodutide (bi 456906) corpus
4
Preclinical
10
Observational
3
Open-label
11
Randomised
5
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated GLP-1/glucagon dual receptor agonists in adults with metabolic dysfunction-associated steatohepatitis (MASH). Four trials involving 673 participants were analyzed, revealing significant effects on MASH resolution and liver fat reduction. Adverse events such as nausea and vomiting were reported more frequently.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
RR 2.98 for MASH resolution without worsening of fibrosis; 95% CI 2.09-4.24; k=2.n=673Phase 22023

Abstract

The authors’ words, as Digestive diseases (Basel, Switzerland) supplied them

<h4>Background</h4>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively.<h4>Methods</h4>In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis.<h4>Results</h4>Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09-4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01-1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI -55.24 to -37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97-6.49). ALT (MD -20.38 IU/L, 95% CI -33.00 to -7.75), AST (MD -18.80 IU/L), body weight (MD -4.36%) and systolic blood pressure (MD -5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent.<h4>Conclusions</h4>Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.

Background

This paper addresses the clinical question of whether GLP-1/glucagon dual receptor agonists can effectively treat metabolic dysfunction-associated steatohepatitis (MASH). Previous research has indicated a need for effective therapies for MASH, but no meta-analysis had specifically evaluated this drug class. The findings may provide insights into the potential benefits and risks of these dual agonists in managing MASH.

Methods

The study is a registered systematic review and meta-analysis that included placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. A total of four trials were pooled, involving 673 participants, using DerSimonian-Laird random-effects models for analysis. The primary outcome was MASH resolution, with secondary outcomes including liver fat reduction and liver enzyme levels.

Results

The primary endpoint showed an RR of 2.98 for MASH resolution without worsening of fibrosis (95% CI 2.09-4.24; k=2). Additionally, a borderline exploratory signal for fibrosis improvement was noted with an RR of 1.38 (95% CI 1.01-1.88; p=0.044; k=2). Relative liver fat decreased by 46.24% (95% CI -55.24 to -37.24), and there was an RR of 4.39 for achieving ≥30% liver fat reduction (95% CI 2.97-6.49).

Interpretation

The findings suggest that GLP-1/glucagon dual receptor agonists may improve MASH resolution and reduce liver fat, aligning with some prior literature on the efficacy of GLP-1 agonists. However, the effect sizes for some outcomes, particularly the exploratory fibrosis signal, may not be clinically meaningful given their borderline significance. Limitations such as small sample sizes and potential confounding factors related to adverse events should be considered when interpreting these results.

Key findings

  • RR 2.98 for MASH resolution without worsening of fibrosis; 95% CI 2.09-4.24; k=2.
  • RR 1.38 for exploratory fibrosis improvement; 95% CI 1.01-1.88; p=0.044; k=2.
  • Relative liver fat fell by 46.24%; 95% CI -55.24 to -37.24.
  • RR 4.39 for ≥30% liver fat reduction; 95% CI 2.97-6.49.
  • MD -20.38 IU/L for ALT; 95% CI -33.00 to -7.75.
  • MD -4.36% for body weight.

Limitations

  • small n=673 across four trials
  • borderline significance for exploratory fibrosis improvement
  • potential confounding from gastrointestinal adverse events
  • short follow-up duration not specified

Elsewhere in the Survodutide (BI 456906) corpus

DVisceral and Ectopic Fat Remodeling with Incretin-Based Therapies in Type 2 Diabetes: Human Imaging Evidence.Journal of multidisciplinary healthcare · 2026reviewACardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2024 · n=5530 · Hazard ratio for primary endpoint was 0.89 (95% CI 0.67-1.18; p<0.0001 for non-inferiority).HumanASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2023 · n=752 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2.HumanASurvodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.Contemporary clinical trials · 2026 · 18.7% body-weight reduction at 46 weeks.reviewCNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.Diabetes, obesity & metabolism · 2026 · Not reported in abstract.AnimalASurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026 · -8.2% weight change in the 3.6-mg group at week 76, n=250, 95% CI -9.2 to -7.2Human